Oxator 50 Mg (Oxaliplatin) Injection

Introduction

Oxator 50 mg (Oxaliplatin) Injection represents a cornerstone in modern colorectal cancer treatment protocols. This platinum-based antineoplastic agent, manufactured by Eskayef Pharmaceuticals Ltd. and supplied by Orio Pharma, delivers precise and effective therapy for both adjuvant treatment of stage III colon cancer and advanced colorectal cancer. With Orio Pharma’s commitment to worldwide delivery within 3-7 working days, healthcare providers can ensure timely access to this critical oncology medication, enhancing treatment outcomes for colorectal cancer patients.

Therapeutic Applications

Oxator is specifically indicated for use in combination with infusional 5-fluorouracil/leucovorin for:

Adjuvant Treatment

For stage III colon cancer patients who have undergone complete resection of the primary tumor
Provides vital post-surgical therapy to eliminate microscopic disease
Significantly reduces the risk of cancer recurrence
Enhances disease-free and overall survival rates

Advanced Colorectal Cancer

Effective treatment option for metastatic or locally advanced colorectal cancer
Provides meaningful improvement in progression-free survival
Component of standard-of-care regimens for advanced disease
Maintains quality of life while addressing disease progression

Mechanism of Action

Oxator’s powerful therapeutic effect stems from its sophisticated mechanism of action:

Platinum-Containing Complex: Similar to cisplatin but with improved side effect profile
Alkylating Properties: Forms cross-links within and between DNA strands
Intracellular Activation: Undergoes hydrolysis inside cancer cells to become active
DNA Binding: The platinum compound binds to DNA, creating both inter- and intra-strand cross-links
Replication Inhibition: These cross-links prevent DNA replication and transcription
Cell Death Induction: The cumulative damage to DNA leads to programmed cell death (apoptosis)

This multi-step process makes Oxator particularly effective against rapidly dividing colorectal cancer cells while working synergistically with fluoropyrimidines like 5-fluorouracil.

Dosage and Administration

Oxator requires precise administration protocols to ensure optimal efficacy and safety:

Adjuvant Therapy (Stage III Colon Cancer)

Standard Dose: 85 mg/m² intravenously every 2 weeks for 12 cycles
Administration: IV infusion over 2-6 hours, dissolved in 250-500 ml of 5% glucose solution
Dose Adjustment: Reduce to 75 mg/m² after recovery from toxicity if necessary
Sequence: Administer before fluoropyrimidines in combination therapy

Advanced Colorectal Cancer

Standard Dose: 85 mg/m² intravenously every 2 weeks until disease progression or unacceptable toxicity
Administration: IV infusion over 2-6 hours, dissolved in 250-500 ml of 5% glucose solution
Dose Adjustment: Reduce to 65 mg/m² after recovery from toxicity if necessary
Sequence: Administer before fluoropyrimidines in combination therapy

Clinical Considerations

Contraindications

Oxator should not be administered in cases of:

Pregnancy
Peripheral neuropathy with functional impairment
Severe renal impairment

Drug Interactions

Healthcare providers should be aware of potential interactions:

May decrease plasma levels of digoxin
Increased risk of toxicity with nephrotoxic medications
When used with taxane derivatives (docetaxel, paclitaxel), sequential administration is recommended, with taxanes administered before Oxator

Side Effects Profile

Common adverse reactions include:

Gastrointestinal: Nausea, diarrhea, vomiting, abdominal pain, constipation, anorexia, stomatitis
Hematological: Anemia, thrombocytopenia, leukopenia, neutropenia
Neurological: Peripheral neuropathy, dizziness, headache
Hepatic: Elevated aspartate and alanine transaminases, increased total bilirubin
Constitutional: Fatigue, fever, pain, insomnia
Dermatological: Rash, alopecia, hand-foot syndrome
Respiratory: Dyspnea, cough, rhinitis, epistaxis, pharyngitis
Other: Electrolyte disturbances, injection site reactions, arthralgia

Safety Precautions

Oxator administration requires several important safety measures:

Specialized Supervision: Should only be administered under the supervision of experienced cancer chemotherapy physicians
Handling Procedures: Appropriate precautions for handling and disposal of cytotoxic agents should be followed
Neurological Monitoring: Regular assessment of neurological status is essential, with dose reductions for prolonged or severe symptoms
Hematological Monitoring: Blood counts must be monitored during treatment, and courses should not be repeated until adequate recovery
Equipment Considerations: Avoid using aluminum-containing needles or IV administration sets as aluminum may degrade platinum compounds
Special Populations: Use with caution in elderly patients and those with moderate renal impairment

Preparation and Storage

Proper preparation and storage are critical for maintaining Oxator’s efficacy:

Reconstitution

For 50 mg vial: Reconstitute with 10 ml of water for injection or 5% dextrose
Further Dilution: Reconstituted solution must be further diluted with 250-500 ml of 5% dextrose injection before administration

Storage Guidelines

Intact Vials: Store at 15-30°C; do not freeze
Reconstituted Solution: May be stored at 2-8°C for up to 24 hours
Diluted Solutions: Stable for up to 6 hours at 20-25°C or up to 24 hours under refrigeration (2-8°C)

Manufacturing Excellence

Oxator 50 mg is manufactured by Eskayef Pharmaceuticals Ltd., one of Bangladesh’s premier pharmaceutical companies. Since 1990, when Eskayef acquired the Bangladesh operation of SK&F, USA, they have built a reputation for world-class manufacturing and unwavering quality standards. With over three decades of pharmaceutical excellence, Eskayef ensures that each vial of Oxator meets the highest standards for efficacy, safety, and quality.

Supply and Distribution

Orio Pharma serves as the dedicated supplier for Oxator, specializing exclusively in high-quality oncology medications. Founded in June 2019, Orio Pharma is driven by a mission to make critical cancer treatments accessible worldwide. Their core values of compassion, integrity, innovation, and collaboration inform every aspect of their service, from quality assurance to logistics. With a commitment to worldwide delivery within 3-7 working days, Orio Pharma ensures that Oxator reaches healthcare providers promptly, addressing the time-sensitive nature of cancer treatment.

Conclusion

Oxator 50 mg (Oxaliplatin) Injection represents an essential component in the contemporary management of colorectal cancer. Its established efficacy in both adjuvant therapy for stage III colon cancer and treatment of advanced colorectal cancer makes it indispensable in oncology practice. Manufactured to the highest standards by Eskayef Pharmaceuticals and supplied with dedication by Orio Pharma, Oxator delivers the quality, reliability, and therapeutic efficacy that healthcare professionals and patients depend on in their fight against colorectal cancer. With precise dosing guidelines, comprehensive safety information, and worldwide availability, Oxator stands as a cornerstone of modern colorectal cancer treatment protocols.

For complete prescribing information, clinical support, or to place an order, healthcare professionals are encouraged to contact Orio Pharma’s specialized oncology team today.